Taiwan Bio Therapeutics (台寶生醫) has recently announced its receipt of a certification from the Industrial Development Bureau under the Ministry of Economic Affairs, recognizing the company as a "technology-based enterprise with market potential." With this approval, the company plans to proceed with its IPO application according to its planned timeline.
Taiwan Bio Therapeutics generates revenue by providing early-stage, high-end cell therapy Contract Development and Manufacturing Organization (CDMO) services. This forms the foundation for its operations in the development of new cell therapies. Thanks to the success of its strategies, the company has seen its revenue double for three consecutive years, maintaining a gross margin above 60%. With multiple products from domestic and international clients entering clinical phases, the company remains optimistic about its performance in the upcoming quarter.
CEO Cyrus Yang (楊鈞堯) stated that the company's CDMO business has secured a strong foothold and will continue its international expansion following its set goals. The next phase will focus on accelerating new drug development. Taiwan Bio Therapeutics currently has two major product lines: mesenchymal stem cells (MSC) and regulatory T cells (Treg). The MSC product line includes three key investigational drugs: Chondrochymal for the treatment of degenerative arthritis (currently applying for Phase III clinical trials), Biochymal for chronic non-healing wounds (in Phase II trials), and OmniMSC for acute myocardial infarction (in Phase I trials). Additionally, the company has collaborated with UC Davis on gene-modified MSC therapy for critical limb ischemia, MSC/VEG, which has completed preclinical studies.
The first three investigational drugs target the Taiwanese market and will be distributed through partnerships with local distributors. Taiwan Bio Therapeutics has already signed a memorandum of understanding (MOU) with a distributor for Chondrochymal, positioning it strategically in the market. MSC/VEG is expected to apply for Phase I clinical trial approval from the US FDA within this year.
Regarding the regulatory T cell product line, the investigational drug TregCel (TRK-001), aimed at treating solid organ transplant rejection, has received FDA approval for Phase II clinical trials and is currently applying for Phase II trials in Taiwan. The US market is the primary focus for TregCel, which is poised to become a blockbuster drug for the company.
Cyrus Yang highlighted that since 2010, the US FDA has approved a total of 36 gene and cell therapy products, with the majority being fast-tracked in the past three years. The FDA predicts that 8 to 10 cell therapy products will be approved annually in the future, marking cell therapy as a major trend in global new drug development.
Yang also pointed out that the six gene-modified cell therapies currently on the market generated a combined revenue of $2.682 billion in 2022, underscoring the significant demand in the cell therapy market. Notably, all six therapies primarily target cancer, indicating a substantial unmet need in the non-cancer sector, which holds considerable potential for further development.
Taiwan Bio Therapeutics is focusing on developing drugs for autoimmune and inflammatory diseases. The company's two leading investigational drugs, TRK-001 and MSC/VEG, will both launch global multicenter clinical trials.
Resource (mandarin): 台寶生醫獲科技事業核准函 將申請IPO
